The reactions of a series of potentially tridentate ligands, derived from single amino acids or amino acid analogues, with[NEt
4]
2[ReBr
3(CO)
3] have been investigated. The model compounds [Re(CO)
3Br{(2-pyridylmethyl)NH
2}] (
1) and [Re(CO)
3{(2-pyridylmethyl)
2NH}]Br (
2) were also prepared and structurally characterized. With ligands possessing two pyridylappendages, (2-pyridylmethyl)
2NX (X = -CH
2CO
2H, -CH
2CO
2Et, -CH
2CH
2CO
2H, -CH
2CH
2CO
2Et, -CH
2CH
2CH
2CH
2CH(NHCO
2tBu)CO
2H), complexes of the type [Re(CO)
3(ligand)]Br (
3-
6) were isolated. All possess the
fac-{Re(CO)
3N
3}coordination geometry in the cationic molecular unit. Similarly, the ligands with the imidazolyl arms (2-pyridylmethyl){2-(1-methylimidazolyl)methyl}NCH
2CO
2Et and {2-(1-methylimidazolyl)methyl}
2NCH
2CO
2Et, complexes
7 and
8 of the same[Re(CO)
3(ligand)]Br type, were prepared. Replacement of one pyridyl arm with a thiophene group yielded the complex[Re(CO)
3{(2-pyridylmethyl)N(CH
2CO
2)(2-thiophenemethyl)}] (
9), while additional substitution of X = -H for -CH
2CO
2Hyielded [Re(CO)
3Br{(2-pyridylmethyl)NH(2-thiophenemethyl)}] (
10). In both
9 and
10, the thiophene is uncoordinatedand pendant, and the derivatives display
fac-{Re(CO)
3N
2O} and
fac-{Re(CO)
3N
2Br} coordination geometries, respectively.Crystal data: C
9H
8BrN
2O
3Re (
1), triclinic
P,
a = 8.156(1) Å,
b = 12.077(1) Å,
c = 12.945(2) Å,
= 92.183(3)
,
= 107.848(3)
,
= 100.955(7)
,
V = 1185.1(3) Å,
Z = 4; C
15H
13BrN
3O
3Re (
2), tetragonal
P4
1,
a = 8.6095(3) Å,
c =22.228(1) Å,
V = 1646.9(1) Å
3,
Z = 4; C
17H
14BrN
3O
5Re·CH
3OH (
3), monoclinic
P2
1/
m,
a = 7.4425(3) Å,
b = 9.7596(4)Å,
c = 14.0646(6) Å,
= 97.753(1)
,
V = 1012.26(7) Å
3,
Z = 2; C
19H
19BrN
3O
5Re (
4), tetragonal
P2
1c,
a = 16.895(3)Å,
c = 15.042(3) Å,
V = 4293.7(13) Å
3,
Z = 8; C
18H
20BrN
4O
5Re·CH
3OH·H
2O (
7), monoclinic
P2
1/
c,
a = 10.2816(4) Å,
b = 30.386(1) Å,
c = 14.5810(6) Å,
= 99.868(1)
,
V = 4488.03(3) Å
3,
Z = 8; C
17H
21BrN
5O
5Re·0.5CH
2Cl
2·0.5H
2O(
8), triclinic
P,
a = 11.5363(6) Å,
b = 13.1898(6) Å,
c = 16.4933(8) Å,
= 89.356(1)
,
= 74.907(1)
,
=76.216(1)
,
V = 2349.8(2) Å
3,
Z = 4; C
16H
13N
2O
5ReS (
9), monoclinic
P2
1/
c,
a = 17.2072(7) Å,
b = 8.5853(4) Å,
c =11.5607(5) Å,
= 101.73(1)
,
V = 1672.2(1) Å
3,
Z = 4; and C
14H
12N
2O
3BrReS (
10), triclinic
P,
a = 7.5585(3) Å,
b= 9.7713(4) Å,
c = 11.7103(4) Å,
= 109.566(1)
,
= 98.298(1)
,
= 100.925(1)
,
V = 779.73(5) Å
3,
Z = 2.